A formulation of grape seed, Indian gooseberry, turmeric and fenugreek helps controlling type 2 diabetes mellitus in advanced-stage patients

详细信息    查看全文

• 作者：Sangeeta Banerji ; ^{sangeeta.banerji@phytomedservice.de" class="auth_mail" title="E-mail the corresponding author} ; Shanta Banerjee ^{banerjee@phytomedservice.de" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Polyherbal formulation ; Type 2 diabetes ; Oxidative stress ; Dietary supplement ; Phytotherapy
• 刊名：European Journal of Integrative Medicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：8
• 期：5
• 页码：645-653
• 全文大小：679 K

文摘

The aim of this clinical study was to determine whether an add-on treatment with a herbal product (Plantabetics^®) containing extracts of grape seed, Indian gooseberry, turmeric and fenugreek seeds, improved glycemic control in advanced-stage patients, who were no longer responding to a combination therapy of metformin and sulfonylurea.

Methods

This was an open label, single arm before/after study of 84 days duration. A total of 50 patients with type 2 diabetes, who were on a stable dose of metformin and sulfonylurea but not showing any improvement in diabetic control, were recruited. Patients were not taking any other herbal supplements or medication. They were instructed to take one capsule of the investigational product two times daily along with their diabetes medication. End points were glycated hemoglobin (HbA1c), fasting blood sugar, and postprandial blood sugar. Safety parameters were also evaluated.

Results

Treatment with the investigated herbal product in conjunction with prescribed diabetes medication resulted in a > 1% unit reduction in average glycated hemoglobin value (from 8.8%/73 mmol/mol to 7.5%/58 mmol/mol; p < 0.001) as well as significant reduction in average fasting (from 8.8 mmol/l to 6.6 mmol/l; p < 0.001) and post prandial blood sugar values (14.6 mmol/l to 10.4 mmol/l; p < 0.001) in the majority of the study population. The herbal product was moreover well-tolerated and safe to use.

Conclusions

The investigated product in combination with oral hypoglycemic agents is a promising candidate for regaining glycemic control in advanced-stage type 2 diabetes patients.